Oslo, 22 August 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its second quarter 2023 results today.
“In the first half of this year, Ultimovacs has further advanced the broad evaluation of our therapeutic cancer vaccine UV1 across key indications. Our UV1-103 study in the U.S. continues to demonstrate encouraging and lasting patient survival, a direct measure of clinical benefit in cancer trials. In addition, we recently reached an important milestone with three randomized Phase II studies fully enrolled in different cancer indications. We are eagerly awaiting the forthcoming data these trials will provide, helping us better comprehend UV1’s potential and the benefits it can provide in the clinical outcomes for the patients,” said Carlos de Sousa, CEO of Ultimovacs. “The data from these randomized Phase II studies, expected within the Company’s current financial runway, will guide us on the path towards bringing UV1 to the market and making a positive impact on the lives of cancer patients.”
Second Quarter 2023 Highlights:
Clinical trial enrollment updates
UV1 Phase II Program:
TENDU Phase I trial (prostate cancer) based on the TET technology platform:
Enrollment of 12 patients was completed in mid-December 2022. Readout expected H2 2023.
Financial update
The quarterly report and presentation will be published at 08:00 CEST on 22 August 2023 and will be publicly available on the Ultimovacs website. The presentation by the Company’s management can be followed as a live webcast at 14:00 CEST today, 22 August 2023. Questions can be submitted throughout the event. The webcast is scheduled to conclude at 14:55 CEST.
For further information, please see www.ultimovacs.com or contact:
Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507
Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632
Anne Worsøe, Head of Investor Relations
Email: anne.worsoe@ultimovacs.com
Phone: +47 906 86815
About Ultimovacs
Ultimovacs is a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines with broad applicability. Ultimovacs’ lead cancer vaccine candidate, UV1 is directed against human telomerase (hTERT), an antigen that is present in 85-90% of cancers in all stages of tumor growth. A broad clinical program, with Phase II trials in five cancer indications enrolling more than 670 patients, aims to demonstrate UV1’s impact in combination with other immunotherapies in multiple cancer types expressing telomerase and where patients have unmet medical needs. UV1 is universal, off-the-shelf and easy to use, and is a patented technology owned by Ultimovacs.
In addition, Ultimovacs’ adjuvant platform, based on the proprietary Tetanus-Epitope-Targeting (TET) technology, combines tumor-specific antigens and adjuvant in the same molecule and is in Phase I clinical development.
This information is subject of the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.
This stock exchange announcement was published by Joachim Midttun, Finance Manager at Ultimovacs ASA, on August 22 2023 at 08:00 CET.
Attachments
PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT A LEADING EUROPEAN BREAST CANCER CONFERENCEANGLE presenting two…
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today…
GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY )…
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 22, 2024 / Biophytis SA (Nasdaq:BPTS)(Euronext…
LAKE FOREST, CA / ACCESSWIRE / March 21, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally…
Bring Dementia Education at No Cost to Your Skilled Nursing HomeTUSCALOOSA, AL / ACCESSWIRE /…